Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

This Week's Biotech Stock Star Performers

The biotech industry is poised for robust growth thanks to the increasing demand for personalized treatments, the rise in chronic diseases, a rapidly aging population, the adoption of advanced technologies, and government initiatives. Therefore, to capitalize on the industry’s growth prospects, one could consider buying fundamentally strong biotech stocks Genmab…

StockNews.com

Unleash Gain Potential With 3 Pharma Stocks to Consider

With an increasing demand for treatments of chronic diseases, heightened investments in research and development, and the widespread integration of technology, the pharma industry is primed for success. Amid the solid industry prospects, let’s analyze the gain potential of three pharma stocks: Amneal Pharmaceuticals (AMRX), AbbVie Inc. (ABBV), and GSK…

StockNews.com

Biogen (BIIB): Earnings Alert - Key Insights

Because of its strategic focus on research and therapy improvements for long-term growth, Biogen (BIIB) could come under heat for the mixed outcomes of its recent acquisitions. As stakeholders anticipate the forthcoming earnings release, let's seek insights into the company's future trajectory and implications for BIIB shares. Read on….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Investors Are Flocking to These 2 Medical Stocks

Given the growing demand for healthcare facilities, rapid integration of digital technology, and transformative biotechnology breakthroughs, the medical industry is poised for continued growth and profitability this year and beyond. Amid this, let’s find out why investors are flocking to medical stocks Vertex Pharmaceuticals (VRTX) and McKesson (MCK). Read more….

StockNews.com

Senate hearings expose pharmaceutical companies amidst rising drug prices

This article discusses a contentious hearing on Capitol Hill where pharmaceutical companies faced scrutiny over high drug prices and their impact on health...

Top News

Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug

Viking Therapeutics moved up its timeline for an Eli Lilly-rivaling obesity treatment on Thursday, leading VKTX stock to a record high.

Investors Business Daily

How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month

Cytokinetics has shucked off two high-profile setbacks, leading CYTK stock to double as it looks to take on Bristol in heart disease.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

The Guardian view on India-UK trade talks: don’t make it harder for the health service

Editorial: Britain is pushing for patent changes that could increase the cost of Indian generic drugs, diverting more of the NHS budget to big pharma

The Guardian - UK

Gilead Reports 'Mildly Disappointing' Quarterly Results With An Unexpected High Point

Gilead had a "mildly disappointing" fourth quarter that featured two high-profile misses from HIV drugs. GILD stock hit a four-month low.

Investors Business Daily

3 Growth Pharma Stocks to Guard Your Portfolio

The pharma industry is experiencing significant growth, fueled by rising demand for personalized medicines, a revolutionary wave of drug development and robust government support. Therefore, it could be wise to consider fundamentally strong pharma stocks Zoetis (ZTS), Bristol-Myers Squibb (BMY), and Teva Pharmaceutical Industries (TEVA) to guard your portfolio. Read…

StockNews.com

Eli Lilly & Co. (LLY) Pre-Earnings Moves: Buy or Watch?

Eli Lilly (LLY) saw steady growth in its last reported quarter, driven by sales from its popular diabetes drug Mounjaro. The stock has had an impressive run over the past year. However, will the momentum be sustained following its upcoming earnings release scheduled for tomorrow? Read on.

StockNews.com

Amgen Is Trying To Take On Lilly, Novo In Obesity Treatment — Here's Why Lilly Stock Just Hit A Record

Amgen stock slumped Monday — as Eli Lilly stock hit a record high — after the company unveiled preclinical results for its weight-loss drug.

Investors Business Daily

AMGN Earnings Spotlight: Analyzing Potential Gains

Drug manufacturer Amgen Inc. (AMGN) is actively pursuing strategic collaborations and making noteworthy strides in the realm of obesity treatments. With the company all set to lift the curtains on its fiscal fourth-quarter earnings tomorrow, would it be prudent to take a bullish stance on the stock now? Keep reading…

StockNews.com

Gilead (GILD) Quarterly Earnings: Buy or Sell Signal?

Biotech major Gilead Sciences (GILD) will release its fourth-quarter results on February 6. The company is expected to report growth in earnings over the prior-year quarter, but its revenue is expected to decline. Given the expected decline in its revenue, how should investors play this stock? Read on to learn…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Top News

Novo Holdings Acquires Catalent for .5 Billion, Expands Wegovy Capacity

Novo Holdings has announced its acquisition of Catalent for .5 billion, a move aimed at expanding the production capacity of Wegovy, a drug used for obe...

The Guardian - US

Secretive US rightwing group Alec designs law to give big business ‘complete immunity for bad acts’

Group wrote model legislation to restrict lawsuits under public nuisance laws used to hold opioid makers and others to account

The Guardian - UK

Pharmacies in England and Scotland to offer private Covid jabs – for £45

Pharmadoctor is offering appointments from 1 April for vaccinations and intends to add more pharmacies to its network

StockNews.com

Top 3 Smart Pharma Picks for Good Investments

As global medical needs and technology evolve, the pharmaceutical industry is expected to thrive. Therefore, fundamentally strong pharma stocks Eli Lilly (LLY), AstraZeneca (AZN) and GSK (GSK) might be ideal additions to your portfolio. Read on.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Lucrative Pharma Stocks for Portfolio Success

The pharmaceutical industry holds immense promise due to the rapidly aging population, growing healthcare needs, breakthroughs in new drugs and therapies, and the rise in chronic diseases. Therefore, it could be wise to add fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Eton Pharmaceuticals (ETON), and Viatris (VTRS) to one’s portfolio.…

Salon

FTC probe drugmakers’ patent thickets

The Federal Trade Commission has challenged more than 100 patents drugmakers listed in the FDA’s “Orange Book"

StockNews.com

3 B-Rated Pharma Stocks to Secure Now With Great Value

The pharmaceutical industry, which experienced significant growth over the past years, is anticipated to remain buoyed, driven by the increasing prevalence of chronic diseases, advancements in medical technology, and rising healthcare awareness and expenditure. Given this backdrop, quality pharma stocks Voyager Therapeutics (VYGR), Sanofi (SNY), and Pacira BioSciences (PCRX), with…

International Business Times

Publicis Settles Opioid Case With US States For $350 Mn

Publicis Health will pay $350 million to settle charges from US states that its "predatory and deceptive marketing strategies" worsened the opioid epidemic, New York's top prosecutor said Thursday.

The Guardian - US

Medicare makes opening bid to pharma companies in talks to lower drug costs

Biden administration says public health insurance program has made initial offers for 10 of most commonly used medicines

Salon

Restricting abortion drug access

The Supreme Court will soon decide the fate of access for mifepristone. The fallout of a ban would be tremendous

StockNews.com

AbbVie (ABBV) Earnings Preview: Buy or Sell Opportunities

While AbbVie (ABBV) saw a decrease in net revenues and EPS in the last reported quarter, it raised its 2023 adjusted EPS guidance range. With the company gearing up to report fourth-quarter 2023 results tomorrow, is the stock worth buying today? Keep reading.

1 … 22 23 24 25

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.